Skip to main content
OpenTrials
Completed

NCT Number: NCT01525992

A Community Pharmacy-based Program to Improve Management of Diabetes

In this study the investigators aim to evaluate the impact of a community pharmacy-based program to educate type 2 diabetic patients about medications, life style and self-care.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Taleghani Community Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences

Tehran, Tehran Province, Iran

About this study

Diabetes mellitus type 2 is a progressive metabolic disorder that leads to several morbidities and increased mortality and costs. Studies showed that strict control of blood glucose in diabetic patients reduces patients' risk of microvascular complications. Community pharmacies are a well-placed healthcare facility located at the heart of the community with convenient access to pharmacists as health care professionals. Some studies have shown effective interventions led by community and clinical pharmacist in developed countries. In developing countries, little evidence exists about feasibility of implementing community pharmacy-based services to promote medications adherence, self glucose monitoring and self-care in diabetic patients.

This study is a 2 arm randomized controlled trial. Eligible patients are referred to the community pharmacy from an endocrinologist's office. Of 135 type-2 diabetic patients who will be recruited in the study,68 will be randomly allocated to the intervention arm using telephone balanced blocked randomization method.

A community pharmacy-based program will provide training about medications, life style and self-care to the intervention arm. The control arm (67 patients) will receive usual care during the study period.

The primary outcome of this study is measured as change in hemoglobin A1C pre and post intervention. As the secondary outcome, medications adherence, diabetes self-care activity, body mass index and blood pressure are measured.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetic patients using oral anti diabetic medications.
  • Hemoglobin A1c > 7 within the previous month before recruitment
  • Adequate literacy and ability to use the glucometer.
  • Signing the informed consent

Exclusion criteria

  • Patients requiring adjunct insulin therapy.
  • Patients with concurrent heart failure (stage 4).
  • Patients who fast in Ramadan.
  • Patients receiving diabetes education in other programs.

Treatment and study plan

Community pharmacist-led diabetes education program

Behavioral

A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .

Usual Care

Other

The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.

Primary outcomes

  1. Hemoglobin A1c

    Time frame: Change from baseline (at the point of recruiting) Hemoglobin A1c at 6 months.

    Hemoglobin A1c is measured in all patients prior to participating in the study. All patients will be required to take the test again at the end of the study (6 months) .

Secondary outcomes

  1. Medication adherence

    Time frame: Change from baseline (at the point of recruiting) medication adherence at 6 months.

    Medication adherence will be measured using "Morisky Medication Adherence Questionnaire" which will be translated into Farsi.The validity and reliability of the translated questionnaire will be investigated primarily.

  2. Self-care activity

    Time frame: Change from baseline (at the point of recruiting) Self-care activity at 6 months.

    Self-care activity will be measured using "Diabetes Self-care Activity Measure" questionnaire which will be translated into Farsi. We will investigate the validity and reliability of the translated questionnaire.

  3. Body Mass Index

    Time frame: Change from baseline (at the point of recruiting) Body Mass Index at 6 months.

    Weight (measured in kilograms) divided by square of height (measured in Meters).

  4. Blood pressure

    Time frame: Change from baseline (at the point of recruiting) Blood pressure at 6 months.

Sponsors and collaborators

Lead sponsor

Tehran University of Medical Sciences

Other

Collaborators

  • Research Center for Rational Use of Drugs

Registry information

Official study title

A Community Pharmacy-based Intervention on Type 2 Diabetic Patients to Improve Medications Adherence and Disease Outcomes; a Randomized Controlled Trial.

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Feb 3, 2012
Registry last updated
Apr 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.